Affiliations: [a] Department of Chemistry, University of Kentucky, Lexington, KY, USA | [b] Department of Nephrology and Proteomics Center, University of Louisville, Louisville, KY, USA | [c] Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
Correspondence:
[*]
Correspondence to: Prof. D. Allan Butterfield, Department of Chemistry and Sanders-Brown Center on Aging, University of Kentucky, Lexington, 40506-0055 KY, USA. Tel.: +1 859 257 3184; Fax: +1 859 323 1464; E-mail: [email protected]
Abstract: Alzheimer’s disease (AD), the most common age-related neurodegenerative disorder, is clinically characterized by progressive neuronal loss resulting in loss of memory and dementia. AD is histopathologically characterized by the extensive distribution of senile plaques and neurofibrillary tangles, and synapse loss. Amnestic mild cognitive impairment (MCI) is generally accepted to be an early stage of AD. MCI subjects have pathology and symptoms that fall on the scale intermediately between ‘normal’ cognition with little or no pathology and AD. A rare number of individuals, who exhibit normal cognition on psychometric tests but whose brains show widespread postmortem AD pathology, are classified as ‘asymptomatic’ or ‘preclinical’ AD (PCAD). In this study, we evaluated changes in protein phosphorylation states in the inferior parietal lobule of subjects with AD, MCI, PCAD, and control brain using a 2-D PAGE proteomics approach in conjunction with Pro-Q Diamond phosphoprotein staining. Statistically significant changes in phosphorylation levels were found in 19 proteins involved in energy metabolism, neuronal plasticity, signal transduction, and oxidative stress response. Changes in the disease state phosphoproteome may provide insights into underlying mechanisms for the preservation of memory with expansive AD pathology in PCAD and the progressive memory loss in amnestic MCI that escalates to the dementia and the characteristic pathology of AD brain.
